EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 151 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $136,651 | -30.2% | 24,402 | -34.7% | 0.00% | – |
| Q1 2024 | $195,897 | -57.8% | 37,385 | -57.8% | 0.00% | -100.0% |
| Q4 2023 | $463,823 | +58.8% | 88,685 | +378.7% | 0.00% | – |
| Q3 2023 | $292,171 | -65.1% | 18,527 | -56.9% | 0.00% | -100.0% |
| Q2 2023 | $836,289 | +51.6% | 43,019 | +121.2% | 0.00% | 0.0% |
| Q1 2023 | $551,683 | -24.7% | 19,446 | -22.4% | 0.00% | 0.0% |
| Q4 2022 | $732,212 | -99.9% | 25,050 | +7.5% | 0.00% | 0.0% |
| Q3 2022 | $615,480,000 | +338.4% | 23,296 | +637.2% | 0.00% | – |
| Q2 2022 | $140,399,000 | -23.6% | 3,160 | -14.9% | 0.00% | – |
| Q1 2022 | $183,707,000 | -43.6% | 3,712 | -42.0% | 0.00% | – |
| Q4 2021 | $325,735,000 | -50.5% | 6,397 | -45.8% | 0.00% | -100.0% |
| Q3 2021 | $657,814,000 | +253.2% | 11,793 | +171.0% | 0.00% | – |
| Q2 2021 | $186,223,000 | +99.2% | 4,351 | +94.2% | 0.00% | – |
| Q1 2021 | $93,498,000 | +8.4% | 2,240 | +21.0% | 0.00% | – |
| Q4 2020 | $86,248,000 | -32.4% | 1,852 | -38.3% | 0.00% | – |
| Q3 2020 | $127,525,000 | +48.2% | 3,002 | +67.4% | 0.00% | – |
| Q2 2020 | $86,028,000 | -91.5% | 1,793 | -91.8% | 0.00% | -100.0% |
| Q1 2020 | $1,011,356,000 | +620.3% | 21,986 | +840.8% | 0.00% | – |
| Q4 2019 | $140,407,000 | -87.3% | 2,337 | -88.1% | 0.00% | -100.0% |
| Q3 2019 | $1,109,677,000 | +3.9% | 19,616 | +2.2% | 0.00% | 0.0% |
| Q2 2019 | $1,068,221,000 | +713.1% | 19,185 | +637.3% | 0.00% | – |
| Q1 2019 | $131,375,000 | +709.1% | 2,602 | +545.7% | 0.00% | – |
| Q4 2018 | $16,237,000 | -92.4% | 403 | -86.9% | 0.00% | – |
| Q3 2018 | $212,912,000 | -8.4% | 3,071 | 0.0% | 0.00% | – |
| Q2 2018 | $232,352,000 | -59.9% | 3,071 | -72.0% | 0.00% | -100.0% |
| Q1 2018 | $578,852,000 | -6.3% | 10,986 | -5.0% | 0.00% | 0.0% |
| Q4 2017 | $617,535,000 | -12.5% | 11,560 | -2.3% | 0.00% | -50.0% |
| Q3 2017 | $705,839,000 | +264.3% | 11,835 | +381.9% | 0.00% | +100.0% |
| Q2 2017 | $193,754,000 | +50.9% | 2,456 | +58.7% | 0.00% | – |
| Q1 2017 | $128,391,000 | +20.2% | 1,548 | +15.0% | 0.00% | -100.0% |
| Q4 2016 | $106,792,000 | +27.9% | 1,346 | +12.8% | 0.00% | – |
| Q3 2016 | $83,510,000 | +503.0% | 1,193 | +234.2% | 0.00% | – |
| Q2 2016 | $13,848,000 | -92.7% | 357 | -83.3% | 0.00% | – |
| Q4 2015 | $189,044,000 | +50.0% | 2,132 | +25.3% | 0.00% | – |
| Q3 2015 | $125,999,000 | +118.5% | 1,702 | +138.7% | 0.00% | – |
| Q2 2015 | $57,653,000 | +4199.3% | 713 | +572.6% | 0.00% | – |
| Q3 2014 | $1,341,000 | -73.5% | 106 | -70.0% | 0.00% | – |
| Q2 2014 | $5,058,000 | – | 353 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Hudson Executive Capital LP | 1,323,794 | $79,534,000 | 3.54% |
| Park West Asset Management LLC | 1,171,880 | $70,406,000 | 2.96% |
| Matarin Capital Management, LLC | 170,008 | $10,214,000 | 0.98% |
| Smith, Graham & Co., Investment Advisors, LP | 140,014 | $8,412,000 | 0.82% |
| Capital Impact Advisors, LLC | 33,725 | $2,026,000 | 0.71% |
| U S GLOBAL INVESTORS INC | 18,800 | $1,130,000 | 0.51% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 187,989 | $11,294,000 | 0.37% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,442,000 | 0.34% |
| GLOBEFLEX CAPITAL L P | 18,751 | $1,127,000 | 0.21% |
| Foundry Partners, LLC | 70,357 | $4,227,000 | 0.16% |